# Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct03604419` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03604419](<https://clinicaltrials.gov/study/NCT03604419>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03604419

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

## Technical summary

Registry record NCT03604419. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-13 (actual); primary completion 2019-07-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 214 participants (enrolled count; ClinicalTrials.gov record NCT03604419, source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)
- Started: 2018-06-13 (actual) (ClinicalTrials.gov record NCT03604419, source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)
- Primary completion: 2019-07-23 (actual) (ClinicalTrials.gov record NCT03604419, source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)
- Completion: 2019-07-23 (actual) (ClinicalTrials.gov record NCT03604419, source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03604419, source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03604419-2020-01-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): PB-119 100 μg+ Glucophage®
- Intervention (Drug): PB-119 150 μg+ Glucophage®
- Intervention (Drug): PB-119 200 μg+ Glucophage®
- Intervention (Drug): PB-119 placebo + Glucophage®
- Lead sponsor: PegBio Co., Ltd.
- Lead sponsor class: OTHER
- Collaborator: Covance
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: PegBio Co., Ltd. (`cardio:org-pegbio-co-ltd`)
- Registry lists this organization as a collaborator: Covance (`cardio:org-covance`)

## Provenance

Content hash: bd1bdaf1236cf77b089be465d4d869593c2bf92f0a3ae3d72d04d96eec469e99
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
